Article

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatment

2020-10-17

Abstract excerpt

<h4>Summary</h4> Prostate cancers generally lack T cell infiltration and display resistance to immune checkpoint therapies (ICT). We found that intermittent but not daily dosing of PI3Kα/β/δ inhibitor BAY1082439 on a Pten -null spontaneous prostate cancer model could overcome ICT resistance and unleash CD8 + T cell-dependent anti-tumor immunity in vivo . Mechanistically, BAY1082439 converts Pten -null cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f3200d62-e319-5cc6-9a5d-07096c8afea9
DOI: 10.1101/2020.10.17.343608

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatmentDOI 10.1101/2020.10.17.343608Read

Spatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancerSemantic proximity Read

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancerSemantic proximity Read

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity Read

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.Semantic proximity Read

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Anti-Inflammation Set for Prostate Cancer ImmunoevasionSemantic proximity Read

Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic ReprogrammingSemantic proximity Read

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read

Emerging role of PTEN loss in evasion of the immune response to tumours.Semantic proximity Read

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old StorySemantic proximity Read

Targeting the TLK1-Nek1-Mediated Activation of YAP1 Attenuates PD-L1 and Inflammation Set for Prostate Cancer ImmunoevasionSemantic proximity Read

Prioritization of prostate cancer to immune checkpoint therapy by ranking tumors along IFN-γ axis and identification of immune resistance mechanismsSemantic proximity Read